---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093295"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:59:10.873077+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio reports Q2 net loss of $17.0M; bempikibart AD trial enrollment completed at 121 patients

## Summary
- Net loss $17.0M ($1.42/share) vs $5.8M ($16.69) in Q2 2023; R&D expense rose to $13.4M from $8.0M.
- Cash and investments $107.6M as of June 30; expected funding into mid-2026.
- Completed enrollment in bempikibart AD Phase 2 trial (121 patients); topline results on track for Q4 2024.
- ADX-097 Phase 2 basket trial for renal diseases enrolling; initial open-label data expected by year-end 2024.
- Bempikibart AA Phase 2 topline results also expected in Q4 2024.

## SEC filing metadata
- accession: 0000950170-24-093295
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000095017024093295/0000950170-24-093295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000095017024093295/qttb-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093295
- JSON: https://secwatch.observer/filing/0000950170-24-093295.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093295.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.